

Correlation between Vatarakta and Hyperuricemia: Bridging Classical Ayurvedic Concepts with Molecular Mechanisms

Dr. Manaswini Singh¹, Dr. Rajesh Sharma², Dr. Sakshi Sharma³,
Dr. Mradu Gupta⁴

¹PG Scholar, Dravyaguna Vigyana, Ayurvedic & Unani Tibbia College & Hospital, Karol Bagh, New Delhi, University of Delhi

²Professor, Dravyaguna Vigyana, Ayurvedic & Unani Tibbia College & Hospital, Karol Bagh, New Delhi, University of Delhi

³Senior Research Officer, Central Ayurveda Research Institute, West Punjabi Bagh, New Delhi

⁴Professor, Department of Plant Molecular Biology, University of Delhi, South Campus

Abstract

Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid levels and is the primary risk factor for gout, driven by dysregulated purine metabolism, oxidative stress, endothelial dysfunction, and NLRP3 inflammasome-mediated inflammation. In *Ayurveda*, *vatarakta* is a classical inflammatory disorder with comparable clinical manifestations, attributed to *agnimandya*, *ama*, *rakta duṣṭi*, *srotorodha* and *vāta prakopa*. This review examines the functional correlation between the *Ayurvedic* pathogenesis of *Vatarakta* and the molecular mechanisms underlying hyperuricemia and gout. It highlights conceptual parallels between classical *Ayurvedic* principles and contemporary evidence on metabolic dysregulation, oxidative stress, vascular dysfunction, monosodium urate crystal deposition, and inflammatory signaling. The review also discusses the therapeutic potential of *Ayurvedic* medicinal plants with antioxidant, anti-inflammatory, xanthine oxidase inhibitory, and uricosuric properties. Although these correlations are interpretative rather than equivalent, integrating *Ayurvedic* concepts with modern molecular insights provides a promising framework for future mechanistic research and evidence-based integrative management of hyperuricemia.

Keywords: Hyperuricemia, *Vatarakta*, *Ayurveda*

Introduction

Hyperuricemia is a metabolic disorder characterized by persistently elevated serum uric acid levels resulting from increased purine metabolism, reduced renal urate excretion or both. It is the primary risk factor for gout an inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals within joints and surrounding tissues. Beyond gout, hyperuricemia is increasingly recognized as a systemic metabolic disorder associated with chronic kidney disease, hypertension, metabolic syndrome, insulin resistance and cardiovascular diseases. Recent studies have identified oxidative stress,

endothelial dysfunction, activation of the NLRP3 inflammasome and pro-inflammatory cytokine signaling as key molecular mechanisms underlying disease progression.

In *Ayurveda*, *Vatarakta* is a well-described inflammatory disorder that closely resembles the clinical manifestations of gout. Classical *Ayurvedic* texts including the *Charaka Samhita*, *Sushruta Samhita*, *Ashtanga Hridaya* and *Madhava Nidana* describe its pathogenesis as a sequential process involving *Agnimandya* (impaired metabolism), *Ama* formation, *Rakta Duṣṭi*, *Srotorodha* (obstruction of physiological channels) and *Vata Prakopa* culminating in severe pain, swelling, erythema, burning sensation and progressive joint dysfunction. Unlike the reductionist approach of modern medicine *Ayurveda* interprets disease as a systemic disturbance involving metabolism, circulation, tissue homeostasis and neurovascular regulation.

Although *Vatarakta* is frequently correlated with gout because of their similar clinical features the two should not be regarded as identical disease entities. *Ayurveda* explains disease through functional physiological disturbances whereas modern medicine focuses on molecular and cellular mechanisms. Nevertheless, advances in systems biology and immune-metabolism have revealed striking functional parallels between these perspectives providing opportunities for scientific integration.

This review critically explores the relationship between the *Ayurvedic* pathogenesis of *Vatarakta* and the molecular mechanisms underlying hyperuricemia and gout. By correlating classical concepts with contemporary evidence on metabolic dysregulation, oxidative stress, endothelial dysfunction, inflammasome activation and inflammatory signaling, the review aims to establish a scientifically plausible framework that may support future mechanistic research and evidence-based integration of *Ayurvedic* interventions in the management of hyperuricemia.

1. *Agnimandya* and Metabolic Dysregulation

In *Ayurveda*, *Agni* represents the fundamental principle governing digestion, metabolism and tissue transformation. Impairment of *jatharagni* and *dhatvagni* (*Agnimandya*) results in defective metabolism and the formation of *Ama*, initiating the pathological cascade in *Vatarakta* (*Charaka Samhita*, *Chikitsa Sthana* 15 & 29).^[1] Modern research similarly identifies Hyperuricemia as a consequence of systemic metabolic dysregulation. Excessive intake of purine-rich foods, fructose-containing beverages, alcohol and calorie-dense diets enhances ATP degradation and purine catabolism thereby increasing uric acid production through xanthine oxidase.^[2] Obesity and insulin resistance further impair renal urate excretion by altering transporter activity, particularly URAT1 and GLUT9, leading to persistent hyperuricemia.^[3] Although *Agni* cannot be reduced to a single biochemical process, its role in maintaining metabolic equilibrium conceptually parallels mitochondrial energy metabolism, enzymatic regulation and metabolic homeostasis.^[4]

2. *Ama* and Oxidative Stress

Classical *Ayurvedic* texts describe *Ama* as an incompletely metabolized toxic substance possessing *guru* (heavy), *picchila* (sticky) and *srotorodhakara* (obstructing) properties that promote inflammation and disease (*Charaka Samhita*, *Sutra Sthana* 28).^[5] Current evidence demonstrates that chronic hyperuricemia is associated with excessive production of reactive oxygen species (ROS) due to increased xanthine oxidase activity.^[6] ROS induce lipid peroxidation, DNA damage, mitochondrial dysfunction, endothelial injury and activation of redox-sensitive transcription factors such as NF-κB, thereby promoting chronic inflammation.^[7]

Furthermore, oxidative stress activates the NLRP3 inflammasome resulting in caspase-1 activation and maturation of IL-1 β a key cytokine responsible for acute gouty inflammation.^[8] The persistent accumulation of oxidative metabolites and inflammatory mediators closely resembles the *Ayurvedic* description of *Ama*, suggesting that *Ama* may represent a functional state of metabolic toxicity rather than a discrete chemical entity.^[9]

3. Rakta Duṣṭi and Endothelial Dysfunction

Rakta dhatu is regarded as the tissue responsible for nourishment, complexion, vitality, and tissue perfusion. Vitiating of *rakta* (*rakta duṣṭi*) manifests as redness (*raga*), burning sensation (*daha*), swelling (*shotha*), and pain (*shoola*), which are characteristic features of *Vatarakta* (Sushruta Samhita, Nidana Sthana 1).^[10]

Experimental studies have shown that elevated uric acid directly impairs endothelial function by reducing nitric oxide bioavailability, increasing oxidative stress, stimulating vascular smooth muscle proliferation and enhancing expression of adhesion molecules such as VCAM-1 and ICAM-1.^[11] Endothelial injury also promotes cytokine production and leukocyte recruitment contributing to chronic vascular inflammation and tissue damage. These vascular changes offer a plausible molecular explanation for *rakta duṣṭi*, emphasizing dysfunction of the vascular compartment rather than alterations in blood alone.

4. Srotorodha and Monosodium Urate Crystal Deposition

The concept of *srotas* encompasses channels responsible for transport of nutrients, metabolites, and waste products. Obstruction of these channels (*srotorodha*) disrupts physiological flow, impairs tissue nourishment, and aggravates *Vāta* (Charaka Samhita, Vimana Sthana 5).^[12] In hyperuricemia, persistent supersaturation of uric acid results in the formation and deposition of monosodium urate (MSU) crystals within synovial tissues. These crystals activate resident macrophages, stimulate inflammatory responses, and progressively damage cartilage and bone.^[13] Hyperuricemia also induces endothelial dysfunction and microvascular impairment, limiting tissue perfusion and promoting chronic inflammation.^[14]

Thus, *Srotorodha* may be interpreted as a broader functional disturbance involving crystal deposition, impaired microcirculation, endothelial dysfunction and altered cellular communication rather than merely physical obstruction.

5. Vāta Prakopa and Neuroinflammation

According to *Ayurveda*, *Vāta* governs movement, neural conduction, and sensory perception. In *Vatarakta*, obstruction of *Vāta* by vitiated *Rakta* produces intense pain and restricted joint function (Charaka Samhita, Chikitsa Sthana 29).^[15] Modern pain biology demonstrates that MSU crystals activate macrophages, neutrophils and mast cells, leading to release of IL-1 β , TNF- α , prostaglandins, bradykinin and other inflammatory mediators that sensitize peripheral nociceptors.^[8] Neurogenic inflammation mediated by substance P and calcitonin gene-related peptide (CGRP) further amplifies pain and vascular responses.

These findings provide a mechanistic basis for the severe pain described in *Vatarakta* and suggest that inflammatory pain signalling may represent one component of *Vāta Prakopa*.

6. NLRP3 Inflammasome and the Ayurvedic Concept of Disease Progression

Activation of the NLRP3 inflammasome is now recognized as the pivotal event linking hyperuricemia with acute gouty inflammation. Phagocytosis of MSU crystals activates NLRP3, which recruits ASC (apoptosis-associated speck-like protein containing a CARD) and procaspase-1 to form the inflammasome complex. Activated caspase-1 cleaves pro-IL-1 β into mature IL-1 β , initiating a cascade of inflammatory cytokine production and neutrophil recruitment.^[8]

This molecular sequence parallels the *Ayurvedic* progression from *Agnimandya* $\rightarrow$ *Ama* $\rightarrow$ *Rakta Duṣṭi* $\rightarrow$ *Srotorodha* $\rightarrow$ *Vāta Prakopa* $\rightarrow$ *Vatarakta* where an initial metabolic disturbance evolves into a systemic inflammatory disorder affecting joints and surrounding tissues.

Table 1.1: Functional Correlation between Ayurvedic Concepts and Contemporary Molecular Mechanisms

<i>Ayurvedic Concept</i>	Functional Interpretation	Molecular Correlates
<i>Agnimandya</i>	Impaired metabolism	Mitochondrial dysfunction, altered purine metabolism
<i>Ama</i>	Toxic metabolic products	Oxidative stress, ROS, inflammatory mediators
<i>Rakta Duṣṭi</i>	Vascular and blood tissue pathology	Endothelial dysfunction, cytokine activation
<i>Srotorodha</i>	Impaired transport	MSU crystal deposition, microvascular dysfunction
<i>Vāta Prakopa</i>	Disturbed neural regulation	Neuroinflammation, nociceptor sensitiz
<i>Shotha</i>	Inflammatory swelling	Increased vascular permeability
<i>Daha</i>	Burning sensation	IL-1 β , prostaglandins, TNF- α
<i>Raga</i>	Redness	Vasodilation and inflammatory hyperaemia

7. Integrated Pathophysiological Model

The integration of classical *Ayurvedic* concepts with contemporary molecular biology suggests that *Vatarakta* and hyperuricemia share common themes of metabolic dysfunction, inflammation, vascular injury, and progressive tissue damage. While *Ayurveda* explains these events through *Agnimandya*, *Ama*, *Rakta Duṣṭi*, *Srotorodha* and *Vāta Prakopa* modern medicine identifies dysregulated purine metabolism, oxidative stress, endothelial dysfunction, inflammasome activation, and cytokine signalling as key drivers of disease.^[8, 13] Recognizing these functional parallels provides a rational scientific framework for investigating *Ayurvedic* interventions that modulate multiple molecular pathways simultaneously.

Discussion

Recent advances in immunometabolism provide a scientific basis for interpreting several *Ayurvedic* concepts in functional terms. Increased xanthine oxidase activity, excessive reactive oxygen species generation, endothelial injury, and pro-inflammatory cytokine signaling closely resemble the pathological consequences attributed to *ama* and *rakta duṣṭi*. Likewise, MSU crystal deposition and

microvascular dysfunction provide a plausible mechanistic explanation for *srotorodha*, while neuroinflammatory mediators responsible for pain sensitization parallel the clinical manifestation of *vāta prakopa*. These correlations should be viewed as conceptual and functional analogies rather than direct equivalence, preserving the integrity of both traditional *Ayurvedic* theory and contemporary biomedical science.

Overall, this integrative perspective supports a systems-based understanding of inflammatory metabolic disorders by linking traditional *Ayurvedic* principles with current knowledge of molecular immunology and metabolism. Future interdisciplinary research combining *Ayurveda*, molecular biology, metabolomics, systems pharmacology, and well-designed randomized clinical trials will be essential to validate these correlations and develop evidence-based integrative therapeutic strategies for hyperuricemia and related inflammatory disorders.

Conclusion

The present review demonstrates that the *Ayurvedic* concept of *Vatarakta* shares remarkable functional similarities with the contemporary pathophysiology of hyperuricemia and gout particularly in relation to metabolic dysregulation, oxidative stress, endothelial dysfunction, inflammatory signaling and progressive joint damage. Although the conceptual foundations of *Ayurveda* and modern biomedicine differ substantially, advances in molecular medicine provide a scientifically plausible framework for interpreting classical *Ayurvedic* principles in the context of current immunometabolic mechanisms. Rather than representing identical disease entities, *Vatarakta* and hyperuricemia exhibit convergent pathophysiological processes that support meaningful scientific dialogue between the two systems of medicine.

Current evidence is largely derived from preclinical and experimental studies, with limited high-quality clinical validation and inadequate molecular characterization of *Ayurvedic* concepts such as *agni*, *ama* and *rakta duṣṭi*. Future research should integrate molecular biology, multi-omics technologies and systems pharmacology to identify objective biomarkers and elucidate the mechanistic basis of these concepts. Well-designed randomized clinical trials, along with standardization, pharmacokinetic, and safety studies of *Ayurvedic* interventions, are essential to establish their clinical efficacy and facilitate evidence-based integrative management of hyperuricemia.

References

1. Pandey K., Chaturvedi G.N., ed. Charaka Samhita-1 sutrasthana, 4/8, Chaukhamba Bharti Academy, Varanasi reprint 2017, p.71,84.
2. Sun HL, Wu YW, Bian HG, Yang H, Wang H, Meng XM, Jin J. Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia. *Front Pharmacol*. 2021 Jul 14;12:667753. doi: 10.3389/fphar.2021.667753. PMID: 34335246; PMCID: PMC8317579.
3. Dalbeth N., Robinson P.C., Patients with gout: an under-recognised group at high risk of COVID-19, *The Lancet*, Vol. 3(5), May, 2021, E317-E318.
4. Patwardhan B., Mashelkar R.A. Traditional medicine-inspired approaches to drug discovery: can *Ayurveda* show the way forward? *Drug Discov Today*. 2009 Aug;14(15-16):804-11. doi: 10.1016/j.drudis.2009.05.009. Epub 2009 May 27. PMID: 19477288.
5. Pandey K., Chaturvedi G.N., ed. Charaka Samhita-1 sutrasthana, 28/8, Chaukhamba Bharti Academy, Varanasi reprint 2017, p.71,84.

6. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. *Int J Cardiol.* 2016 Jun 15;213:8-14. doi: 10.1016/j.ijcard.2015.08.109. Epub 2015 Aug 14. Erratum in: *Int J Cardiol.* 2023 Sep 15;387:131126. doi: 10.1016/j.ijcard.2023.131126. PMID: 26316329.
7. Rock P.L., Roiser J.P., Riedel W.J., Blackwell A.D., Cognitive impairment in depression: a systematic review and meta-analysis, *Psychological Medicine*, 2014;44(10):2029-2040.
8. So A.K., Martinon F., Inflammation in gout: mechanisms and therapeutic targets, *Nat. Rev. Rheumatol*, 2017, Nov.,13(11):639-647.
9. Roberti P., Tassinari M., Integrative approaches for health: Biomedical research, ayurveda, and yoga. *J Ayurveda Integr Med.*, 2015, Jul-Sep;6(3):213–4. PMCID: PMC4630699.
10. Pandey K., Chaturvedi G.N., ed. *Charaka Samhita-1 Nidana sthana*, 4/8, Chaukhamba Bharti Academy, Varanasi reprint 2017, p.71,84.
11. Richard J., Johnson, G. L., Claudio B., Michel B. C., David F., Miguel A. L., Tony R. M., Orson W. M., David B. M., Laura G. S. L., Eli S., Daniel E., Glenn M., Chertow, Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation, *American Journal of Kidney Diseases*, Volume 71, Issue 6, 2018, Pages 851-865.
12. Pandey K., Chaturvedi G.N., ed. *Charaka Samhita-1 chikitsasthana*, 29/8, Chaukhamba Bharti Academy, Varanasi reprint 2017, p.71,84.
13. Shen X., Wang C., Liang N., Liu Z., Li X., Zhu Z.J., Merriman T.R., Dalbeth N., Terkeltaub R., Changgui L., Huiyong Y., Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout, *Arthritis & Rheumatology*, Vol. 73(9), March, 2021, p.1738-1748.
14. Jessica M., Francesca O., Santo G., Carolina M., Vincenzo M., Regulation of uric acid metabolism and excretion, *International Journal of Cardiology*, Vol. 213, June 2016, p. 8-14.